Non-steroidal mineralocorticoid receptor antagonists and safety FIDELIO-DKD did not show an increase in the anticipated adverse events including AKI, breast hyperplasia, or gynecomastia
There is no evidence that GLP-1-based therapies increase the risk of cancer recurrence, but limited data exist specifically addressing this question
It is known that endogenous levels of GHK peptide naturally decline with age, from roughly 200 ng/ml at age 20 to 80 ng/ml at age 60 [3], and studies have shown that GHK-Cu can reset gene expression of human cells to a healthier state, which has led to breakthroughs in tissue regeneration and wound healing [4, 5, 6]
Patients should never accelerate the titration schedule without medical guidance, as this may worsen side effects without improving therapeutic outcomes
Concentration, volume, lot number, expiration date, storage instructions, and reconstitution guidelines (if applicable) should all be included